MSN Laboratories Initiates Phase III Clinical Trial of Molnupiravir for India
Hyderabad based MSN Laboratories Pvt. Ltd. (MSN) which has been in the forefront of introducing various drugs in the treatment of Covid-19 and its complications, on May 25 announced that it is initiating phase III clinical trial of Molnupiravir capsules for the treatment of Covid-19 in India. The pharma company has made this announcement post its launch of Posaone (Posacanazole) tab and IV in the treatment of black fungus.
MSN has received its clinical trial approval on 19th May 2021, from the Drug Controller General of India's to perform a Molnupiravir Capsules efficacy and safety study on mild to moderate Cocid-19 patients. MSN will start its clinical trials in more than 40 sites across India and the first dosing is expected to begin soon. The clinical trials will be performed on more than 2400 subjects suffering from mild to moderate COVID-19.Molnupiravir is an experimental drug having antiviral properties and is currently under clinical-stage study for Covid treatment. MSN R&D team has developed both the API and formulation, is expecting to launch soon after the successful conclusion of the clinical study followed by regulatory approval.
As part of the COVID treatment range, MSN has already launched Favilow (Favipiravir) in the strengths of 200mg, 400mg and 800mg, Oselow (Oseltamivir) as 75mg capsules and licensed Baridoz (Baricitinib) recently with Eli Lilly. For availability of all Covid drugs from MSN, patients can contact MSN Covid helpline: 91005 91030 or email: customercare@msnlabs.com.
Comments
Post a Comment